Indapta Therapeutics
PrivateLast Round
VC Round
Dec 17, 2024
Total Funding Raised
$54.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Indapta Therapeutics is a biotechnology company developing a proprietary, off-the-shelf, allogeneic FcRγ-deficient natural killer (g-NK) cell therapy platform to treat cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Indapta Therapeutics Comparables
Compare Indapta Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Artiva | 87% | |
| Wugen | 86% | |
| CytoImmune Therapeutics | 85% | |
Indapta Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Dec 17, 2024 | ||||
| Grant | May 15, 2024 | ||||
| Series A | Feb 10, 2022 |
Key People
Founding team and executive leadership
Indapta Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cancer Prevention & Research Institute of Texas | Grant |
| RA Capital Management | VC Round, Series A |
| Vertex Ventures HC | VC Round, Series A |
| Pontifax Venture Capital | VC Round |
| Pontifax Credit | VC Round |
| Cancer Prevention and Research Institute of Texas | Grant |
| Leaps by Bayer | VC Round, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 116% MoM.
- Jul 26, 2026
Monthly visitors increased 37% MoM.
Indapta Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Indapta Therapeutics's valuation, stock price, and market status.